SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Business
BIO 2020: Disruptive Thinking About Addiction Management
The session discussed three “out-of-the-box” innovations that apply to multiple types of addictions.
June 18, 2020
 · 
4 min read
 · 
Gail Dutton
Business
COVID-19 Stresses Manufacturing Capacities and Funders’ Understanding
The race toward a COVID-19 vaccine is focused around scientific development right now, but companies also need to be planning for manufacturing.
June 17, 2020
 · 
4 min read
 · 
Gail Dutton
Policy
FDA Warns Against Co-Administering Remdesivir with Hydroxychloroquine or Chloroquine
The warning came only a few hours after the FDA rescinded Emergency Use Authorization (EUA) for hydroxychloroquine and chloroquine for the treatment of COVID-19.
June 16, 2020
 · 
4 min read
 · 
Gail Dutton
Drug Development
BIO 2020: Are We Ready for Decentralized Clinical Trials?
Decentralized clinical trials gained a foothold in the pharmaceutical industry amidst the COVID-19 pandemic and will continue to be used once the pandemic ends, according to panelists at BIO 2020, speaking Thursday in a virtual session.
June 12, 2020
 · 
4 min read
 · 
Gail Dutton
Business
BIO 2020: Neurodegenerative Therapies Need a Personalized Approach
Biopharmaceutical companies need to look beyond the usual targets when addressing neurodegenerative disorders and also must work to correlate genetic changes to cognitive changes in patients, according to panelists at BIO’s on-demand session, “Battle of the Brains: Rethinking Neurodegenerative Disease Treatment.”
June 11, 2020
 · 
4 min read
 · 
Gail Dutton
Drug Development
Past Vaccine Failures May Reduce COVID-19 Vaccination Rates
With more than 130 COVID-19 vaccines in development around the world, many of them are bound to fail. When they do, will that erode the public trust in the vaccines that are approved? The answer largely depends on where in the development cycle the vaccines fail and the scope of their failure.
June 10, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Personalization, Prediction and Prevention Drive the “Second Transformation of Medicine”
The healthcare system is innovating to address the pain points the pandemic revealed. Specifically, it is becoming more proactive, preventative and personalized.
June 9, 2020
 · 
4 min read
 · 
Gail Dutton
Sven Kili_Vaticanconference2016, Bruce Levine_Cann
Business
BIO 2020: Cell and Gene Therapies Will Dominate Medicine in 30 Years
One day, cell and gene therapies will be as common as small molecules and antibody-based therapies are today, according to panelists at BIO’s June 8 virtual session, “The Next Generation of Medicine: Cell Therapies, Gene Therapies and Beyond.”
June 9, 2020
 · 
4 min read
 · 
Gail Dutton
Business
To Achieve Population-level COVID-19 Vaccinations, First Rebuild Trust
Poll after poll shows that many Americans – 30% to 50% – are unwilling to be vaccinated against COVID-19 once a vaccine becomes available. Meanwhile, officials are banking on widespread vaccination to allow society to return to normal, without masks or social distancing.
June 8, 2020
 · 
5 min read
 · 
Gail Dutton
Drug Development
Imago BioSciences Advances Myelofibrosis Trials, With Phase IIb Prelim Readout Imminent
Imago BioSciences will announce preliminary results from its Phase IIb clinical trial for myelofibrosis (MF) at the 25th European Hematology Association (EHA) Annual Congress that begins June 12, 2020.
June 3, 2020
 · 
3 min read
 · 
Gail Dutton
Business
When Will a COVID-19 Vaccine be Ready… and Why Then?
Industry experts say a vaccine against the SARS-CoV-2 virus will either be ready this fall, at the end of the year or 18 months from now, depending on the vaccine and how they define “ready.”
June 3, 2020
 · 
5 min read
 · 
Gail Dutton
Business
Why Cell and Gene Therapies Need a Paradigm Shift to Enable Commercial Scale-up
Cell and gene therapies must scale up on an industrial level if they are to deliver their full potential to patients worldwide, according to speakers at the International Society of Cell Therapy meeting, ISCT Paris 2020 Virtual, May 29.
June 1, 2020
 · 
5 min read
 · 
Gail Dutton
Business
What Masks Can and Can’t Do, and Why You Should Wear One
Michael Bell, M.D., deputy director of the Division of Healthcare Quality Promotion at the Centers for Disease Control, teamed up with the Pandemic Action Network to help answer such questions and combat misinformation.
May 27, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Hot, Humid Weather Slows SARS-CoV-2 Transmission, but Won’t End the Crisis
A hot, humid summer will slow coronavirus transmission but, on its own isn’t likely to end the COVID-19 pandemic, according to a new study.
May 22, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Mammoth’s GSK Collaboration Aims to End Dichotomy Between Lab and Home Dx Tests, CEO Says
The collaboration, announced Wednesday, aims to make disposable, hand-held diagnostics that are as accurate as lab tests and as easy to use as home pregnancy kits.
May 22, 2020
 · 
4 min read
 · 
Gail Dutton
Load More